ACRS

Aclaris Therapeutics, Inc.

NasdaqGSUSDEQUITY DELAYED

6.42

▲ 0.09 (1.38%)

MARKET · —

Price

Open

6.49

Prev close

6.33

Day high

6.50

Day low

6.29

Volume

2.21M

Market cap

—

P/E (TTM)

—

52W range

1.74 – 6.52

Trailing performance

Price return · vs SPY

Returnvs SPY

+10.90% +12.3%

+16.97% +13.2%

+41.19% +38.1%

+97.84% +86.8%

YTD

+112.96% +100.7%

+254.14% +234.1%

-16.97% -91.1%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

6.07

+5.72% from price

SMA 20

5.85

+9.65% from price

SMA 50

5.44

+17.85% from price

SMA 100

4.91

+30.67% from price

SMA 200

4.02

+59.34% from price

EMA 12

6.09

+5.44% from price

EMA 26

5.83

+10.00% from price

EMA 50

5.51

+16.55% from price

RSI (14)

64.7

Neutral

MACD (12,26,9)

0.25

Hist 0.04

ATR (14)

0.34

5.31% of price

Realised vol 30D

55.3%

Annualised

Bollinger upper

6.66

20, 2σ

Bollinger lower

5.03

20, 2σ

50 / 200 cross

Golden

5.44 vs 4.02

Trend bias

Above 200

+59.34%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.59

Less volatile than market

Correlation to SPY

0.08

Largely independent

Realised vol 30D

55.3%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-36.6%

Peak to trough

Max drawdown 5Y

-96.6%

Peak to trough

ATR 14

0.34

5.31% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 6.42

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

ACRS · links out to the publisher

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade Zacks · 12d ago Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) GlobeNewswire · 16d ago Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates Zacks · 16d ago Aclaris: Q2 Earnings Snapshot Associated Press · 16d ago Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update GlobeNewswire · 16d ago Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? Zacks · 52d ago 3 Penny Stocks Under $5 Backed by Real Revenue Growth MarketBeat · 63d ago Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On Insider Monkey · 76d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.